Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

PURPOSE: This phase I b study evaluated the safety and anti-tumor activity of pembrolizumab in Japanese patients with advanced melanoma. METHODS: Pembrolizumab (2 mg/kg) was given every 3 weeks (Q3W) for up to 2 years or until confirmed progression or unacceptable toxicity. The tumor response was as...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Naoya, Takenouchi, Tatsuya, Fujimoto, Manabu, Ihn, Hironobu, Uchi, Hiroshi, Inozume, Takashi, Kiyohara, Yoshio, Uhara, Hisashi, Nakagawa, Kazuhiko, Furukawa, Hiroshi, Wada, Hidefumi, Noguchi, Kazuo, Shimamoto, Takashi, Yokota, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364262/
https://www.ncbi.nlm.nih.gov/pubmed/28283736
http://dx.doi.org/10.1007/s00280-016-3237-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364262/
https://www.ncbi.nlm.nih.gov/pubmed/28283736
http://dx.doi.org/10.1007/s00280-016-3237-x

Ejemplares similares